EDWARD S. WONG, M.D.; MARY McKEVITT, R.N., B.S.; KATE RUNNING, P.A., W.H.C.S.; GEORGE W. COUNTS, M.D.; MARVIN TURCK, M.D.; WALTER E. STAMM, M.D.
In a randomized crossover trial, 38 women with recurrent urinary tract infections were assigned to use either continuous prophylaxis with trimethoprim-sulfamethoxazole or intermittent self-administered therapy (single-dose trimethoprim-sulfamethoxazole taken for acute urinary symptoms). The infection rate for patients on prophylaxis was 0.2 episodes/patient-year compared with 2.2 infections/patient-year for patients on self-administered therapy (p < 0.001). Thirty-five of thirty-eight symptomatic episodes diagnosed by patients as infection were confirmed microbiologically, and 30 of the 35 infections responded clinically and microbiologically to patient-administered therapy with single-dose trimethoprim-sulfamethoxazole. No complications were seen in the 5 patients in whom therapy failed. The annual costs of prophylaxis and self-therapy were similar ($256 and $239, respectively) and both were less expensive than conventional therapy in women having 2 or more infections per year. In selected women, self-therapy is efficacious and economical compared with conventional therapy or prophylaxis.
WONG ES, McKEVITT M, RUNNING K, et al. Management of Recurrent Urinary Tract Infections with Patient-Administered Single-Dose Therapy. Ann Intern Med. 1985;102:302–307. doi: 10.7326/0003-4819-102-3-302
Download citation file:
Published: Ann Intern Med. 1985;102(3):302-307.
Infectious Disease, Nephrology, Urinary Tract Infection, Urological Disorders.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use